ParkinsonFranceV1, PascalFrancis, Curation, bibRecord, 000656

Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease

Identifieur interne : 000656 ( PascalFrancis/Curation ); précédent : 000655; suivant : 000657

Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease

Auteurs : Vincent Paille [France] ; Philippe Brachet [France] ; Philippe Damier [France]

Source :

Neuroreport : (Oxford) [ 0959-4965 ] ; 2004.

RBID : Pascal:04-0446932

Descripteurs français

Pascal (Inist)
- Lésion, Modèle animal, Pathogénie, Lévodopa, Neurone dopaminergique, Mort cellulaire, Oxidopamine, Locus niger, Dyskinésie, Chronique, Mouvement involontaire, Parkinson maladie, Dopamine, Développement, Rat, Homme, Animal, Contrôle moteur.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Animal, Animal model, Cell death, Chronic, Development, Dopamine, Dopaminergic neuron, Dyskinesia, Human, Involuntary movement, Lesion, Levodopa, Locus niger, Motor control, Oxidopamine, Parkinson disease, Pathogenesis, Rat.

Abstract

The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.

A01	`01`	`1`		`@0 0959-4965`
A03		`1`		`@0 Neuroreport : (Oxf.)`
A05				`@2 15`
A06				`@2 3`
A08	`01`	`1`	`ENG`	`@1 Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease`
A11	`01`	`1`		`@1 PAILLE (Vincent)`
A11	`02`	`1`		`@1 BRACHET (Philippe)`
A11	`03`	`1`		`@1 DAMIER (Philippe)`
A14	`01`			`@1 INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet @2 44093 Nantes @3 FRA @Z 1 aut. @Z 2 aut. @Z 3 aut.`
A14	`02`			`@1 Clinique Neurologique and Centre d'Investigation Clinique, CHU @2 Nantes @3 FRA @Z 3 aut.`
A20				`@1 561-564`
A21				`@1 2004`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 22534 @5 354000113564420350`
A44				`@0 0000 @1 © 2004 INIST-CNRS. All rights reserved.`
A45				`@0 21 ref.`
A47	`01`	`1`		`@0 04-0446932`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Neuroreport : (Oxford)`
A66	`01`			`@0 GBR`
C01	`01`		`ENG`	@0 The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.
C02	`01`	`X`		`@0 002A25E`
C02	`02`	`X`		`@0 002B17A01`
C03	`01`	`X`	`FRE`	`@0 Lésion @5 01`
C03	`01`	`X`	`ENG`	`@0 Lesion @5 01`
C03	`01`	`X`	`SPA`	`@0 Lesión @5 01`
C03	`02`	`X`	`FRE`	`@0 Modèle animal @5 02`
C03	`02`	`X`	`ENG`	`@0 Animal model @5 02`
C03	`02`	`X`	`SPA`	`@0 Modelo animal @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathogénie @5 03`
C03	`03`	`X`	`ENG`	`@0 Pathogenesis @5 03`
C03	`03`	`X`	`SPA`	`@0 Patogenia @5 03`
C03	`04`	`X`	`FRE`	`@0 Lévodopa @2 NK @2 FR @5 04`
C03	`04`	`X`	`ENG`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`04`	`X`	`SPA`	`@0 Levodopa @2 NK @2 FR @5 04`
C03	`05`	`X`	`FRE`	`@0 Neurone dopaminergique @5 05`
C03	`05`	`X`	`ENG`	`@0 Dopaminergic neuron @5 05`
C03	`05`	`X`	`SPA`	`@0 Neurona dopaminérgica @5 05`
C03	`06`	`X`	`FRE`	`@0 Mort cellulaire @5 06`
C03	`06`	`X`	`ENG`	`@0 Cell death @5 06`
C03	`06`	`X`	`SPA`	`@0 Muerte celular @5 06`
C03	`07`	`X`	`FRE`	`@0 Oxidopamine @2 NK @2 FR @5 07`
C03	`07`	`X`	`ENG`	`@0 Oxidopamine @2 NK @2 FR @5 07`
C03	`07`	`X`	`SPA`	`@0 Oxidopamina @2 NK @2 FR @5 07`
C03	`08`	`X`	`FRE`	`@0 Locus niger @5 08`
C03	`08`	`X`	`ENG`	`@0 Locus niger @5 08`
C03	`08`	`X`	`SPA`	`@0 Locus níger @5 08`
C03	`09`	`X`	`FRE`	`@0 Dyskinésie @5 09`
C03	`09`	`X`	`ENG`	`@0 Dyskinesia @5 09`
C03	`09`	`X`	`SPA`	`@0 Disquinesia @5 09`
C03	`10`	`X`	`FRE`	`@0 Chronique @5 10`
C03	`10`	`X`	`ENG`	`@0 Chronic @5 10`
C03	`10`	`X`	`SPA`	`@0 Crónico @5 10`
C03	`11`	`X`	`FRE`	`@0 Mouvement involontaire @5 11`
C03	`11`	`X`	`ENG`	`@0 Involuntary movement @5 11`
C03	`11`	`X`	`SPA`	`@0 Movimiento involuntario @5 11`
C03	`12`	`X`	`FRE`	`@0 Parkinson maladie @5 12`
C03	`12`	`X`	`ENG`	`@0 Parkinson disease @5 12`
C03	`12`	`X`	`SPA`	`@0 Parkinson enfermedad @5 12`
C03	`13`	`X`	`FRE`	`@0 Dopamine @2 NK @2 FR @5 13`
C03	`13`	`X`	`ENG`	`@0 Dopamine @2 NK @2 FR @5 13`
C03	`13`	`X`	`SPA`	`@0 Dopamina @2 NK @2 FR @5 13`
C03	`14`	`X`	`FRE`	`@0 Développement @5 14`
C03	`14`	`X`	`ENG`	`@0 Development @5 14`
C03	`14`	`X`	`SPA`	`@0 Desarrollo @5 14`
C03	`15`	`X`	`FRE`	`@0 Rat @5 54`
C03	`15`	`X`	`ENG`	`@0 Rat @5 54`
C03	`15`	`X`	`SPA`	`@0 Rata @5 54`
C03	`16`	`X`	`FRE`	`@0 Homme @5 55`
C03	`16`	`X`	`ENG`	`@0 Human @5 55`
C03	`16`	`X`	`SPA`	`@0 Hombre @5 55`
C03	`17`	`X`	`FRE`	`@0 Animal @5 69`
C03	`17`	`X`	`ENG`	`@0 Animal @5 69`
C03	`17`	`X`	`SPA`	`@0 Animal @5 69`
C03	`18`	`X`	`FRE`	`@0 Contrôle moteur @5 70`
C03	`18`	`X`	`ENG`	`@0 Motor control @5 70`
C03	`18`	`X`	`SPA`	`@0 Control motor @5 70`
C07	`01`	`X`	`FRE`	`@0 Extrapyramidal syndrome @5 20`
C07	`01`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 20`
C07	`01`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 20`
C07	`02`	`X`	`FRE`	`@0 Système nerveux pathologie @5 21`
C07	`02`	`X`	`ENG`	`@0 Nervous system diseases @5 21`
C07	`02`	`X`	`SPA`	`@0 Sistema nervioso patología @5 21`
C07	`03`	`X`	`FRE`	`@0 Trouble neurologique @5 22`
C07	`03`	`X`	`ENG`	`@0 Neurological disorder @5 22`
C07	`03`	`X`	`SPA`	`@0 Trastorno neurológico @5 22`
C07	`04`	`X`	`FRE`	`@0 Encéphale pathologie @5 23`
C07	`04`	`X`	`ENG`	`@0 Cerebral disorder @5 23`
C07	`04`	`X`	`SPA`	`@0 Encéfalo patología @5 23`
C07	`05`	`X`	`FRE`	`@0 Maladie dégénérative @5 24`
C07	`05`	`X`	`ENG`	`@0 Degenerative disease @5 24`
C07	`05`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 24`
C07	`06`	`X`	`FRE`	`@0 Système nerveux central pathologie @5 25`
C07	`06`	`X`	`ENG`	`@0 Central nervous system disease @5 25`
C07	`06`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 25`
C07	`07`	`X`	`FRE`	`@0 Antiparkinsonien @5 26`
C07	`07`	`X`	`ENG`	`@0 Antiparkinson agent @5 26`
C07	`07`	`X`	`SPA`	`@0 Antiparkinsoniano @5 26`
C07	`08`	`X`	`FRE`	`@0 Système nerveux central @5 27`
C07	`08`	`X`	`ENG`	`@0 Central nervous system @5 27`
C07	`08`	`X`	`SPA`	`@0 Sistema nervioso central @5 27`
C07	`09`	`X`	`FRE`	`@0 Catécholamine @5 28`
C07	`09`	`X`	`ENG`	`@0 Catecholamine @5 28`
C07	`09`	`X`	`SPA`	`@0 Catecolamina @5 28`
C07	`10`	`X`	`FRE`	`@0 Neurotransmetteur @5 29`
C07	`10`	`X`	`ENG`	`@0 Neurotransmitter @5 29`
C07	`10`	`X`	`SPA`	`@0 Neurotransmisor @5 29`
C07	`11`	`X`	`FRE`	`@0 Rodentia @2 NS`
C07	`11`	`X`	`ENG`	`@0 Rodentia @2 NS`
C07	`11`	`X`	`SPA`	`@0 Rodentia @2 NS`
C07	`12`	`X`	`FRE`	`@0 Mammalia @2 NS`
C07	`12`	`X`	`ENG`	`@0 Mammalia @2 NS`
C07	`12`	`X`	`SPA`	`@0 Mammalia @2 NS`
C07	`13`	`X`	`FRE`	`@0 Vertebrata @2 NS`
C07	`13`	`X`	`ENG`	`@0 Vertebrata @2 NS`
C07	`13`	`X`	`SPA`	`@0 Vertebrata @2 NS`
N21				`@1 250`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000D78

Links to Exploration step

Pascal:04-0446932

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</title>
<author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paille">Vincent Paille</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Clinique Neurologique and Centre d'Investigation Clinique, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">04-0446932</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 04-0446932 INIST</idno>
<idno type="RBID">Pascal:04-0446932</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000D78</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000656</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</title>
<author><name sortKey="Paille, Vincent" sort="Paille, Vincent" uniqKey="Paille V" first="Vincent" last="Paille">Vincent Paille</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Brachet, Philippe" sort="Brachet, Philippe" uniqKey="Brachet P" first="Philippe" last="Brachet">Philippe Brachet</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
<author><name sortKey="Damier, Philippe" sort="Damier, Philippe" uniqKey="Damier P" first="Philippe" last="Damier">Philippe Damier</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Clinique Neurologique and Centre d'Investigation Clinique, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>France</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Neuroreport : (Oxford)</title>
<title level="j" type="abbreviated">Neuroreport : (Oxf.)</title>
<idno type="ISSN">0959-4965</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Neuroreport : (Oxford)</title>
<title level="j" type="abbreviated">Neuroreport : (Oxf.)</title>
<idno type="ISSN">0959-4965</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term>
<term>Animal model</term>
<term>Cell death</term>
<term>Chronic</term>
<term>Development</term>
<term>Dopamine</term>
<term>Dopaminergic neuron</term>
<term>Dyskinesia</term>
<term>Human</term>
<term>Involuntary movement</term>
<term>Lesion</term>
<term>Levodopa</term>
<term>Locus niger</term>
<term>Motor control</term>
<term>Oxidopamine</term>
<term>Parkinson disease</term>
<term>Pathogenesis</term>
<term>Rat</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Lésion</term>
<term>Modèle animal</term>
<term>Pathogénie</term>
<term>Lévodopa</term>
<term>Neurone dopaminergique</term>
<term>Mort cellulaire</term>
<term>Oxidopamine</term>
<term>Locus niger</term>
<term>Dyskinésie</term>
<term>Chronique</term>
<term>Mouvement involontaire</term>
<term>Parkinson maladie</term>
<term>Dopamine</term>
<term>Développement</term>
<term>Rat</term>
<term>Homme</term>
<term>Animal</term>
<term>Contrôle moteur</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0959-4965</s0>
</fA01>
<fA03 i2="1"><s0>Neuroreport : (Oxf.)</s0>
</fA03>
<fA05><s2>15</s2>
</fA05>
<fA06><s2>3</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>PAILLE (Vincent)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>BRACHET (Philippe)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>DAMIER (Philippe)</s1>
</fA11>
<fA14 i1="01"><s1>INSERM, Unité 437, CHU de Nantes, 30 bd Jean Monnet</s1>
<s2>44093 Nantes</s2>
<s3>FRA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Clinique Neurologique and Centre d'Investigation Clinique, CHU</s1>
<s2>Nantes</s2>
<s3>FRA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA20><s1>561-564</s1>
</fA20>
<fA21><s1>2004</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>22534</s2>
<s5>354000113564420350</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2004 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>21 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>04-0446932</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Neuroreport : (Oxford)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>The pathogenesis of the motor fluctuations and dyskinesias that complicate levodopa treatment for Parkinson's disease (PD) remains uncertain. To evaluate the relationship between the degree of dopamine neuron loss and the severity of dyskinesias in a rodent model of PD, Sprague-Dawley rats were lesioned unilaterally using different doses of 6-hydroxydopamine injected into the substantia nigra pars compacta (SNc). All rats received two daily oral doses of levodopa for one month. In most of the animals chronic levodopa administration induced abnormal involuntary movements (AIMs), which were in some respects similar to human dyskinesias.We found that a minimum dopamine cell loss of around 95% was required for the development of dyskinesias after one-month of levodopa treatment. Moreover, we observed a positive relationship between the percentage dopaminergic cell loss in the SNc and the severity of levodopa-induced AIMs.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002A25E</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17A01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Lésion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Lesion</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Lesión</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Modèle animal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Animal model</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Modelo animal</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathogénie</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pathogenesis</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Patogenia</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Lévodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Levodopa</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Neurone dopaminergique</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Dopaminergic neuron</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Neurona dopaminérgica</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Mort cellulaire</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Cell death</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Muerte celular</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Oxidopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Oxidopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Oxidopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Locus niger</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Locus niger</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Locus níger</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Chronique</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Chronic</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Crónico</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Parkinson maladie</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Dopamine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Dopamina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>13</s5>
</fC03>
<fC03 i1="14" i2="X" l="FRE"><s0>Développement</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="ENG"><s0>Development</s0>
<s5>14</s5>
</fC03>
<fC03 i1="14" i2="X" l="SPA"><s0>Desarrollo</s0>
<s5>14</s5>
</fC03>
<fC03 i1="15" i2="X" l="FRE"><s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="15" i2="X" l="ENG"><s0>Rat</s0>
<s5>54</s5>
</fC03>
<fC03 i1="15" i2="X" l="SPA"><s0>Rata</s0>
<s5>54</s5>
</fC03>
<fC03 i1="16" i2="X" l="FRE"><s0>Homme</s0>
<s5>55</s5>
</fC03>
<fC03 i1="16" i2="X" l="ENG"><s0>Human</s0>
<s5>55</s5>
</fC03>
<fC03 i1="16" i2="X" l="SPA"><s0>Hombre</s0>
<s5>55</s5>
</fC03>
<fC03 i1="17" i2="X" l="FRE"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC03 i1="17" i2="X" l="ENG"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC03 i1="17" i2="X" l="SPA"><s0>Animal</s0>
<s5>69</s5>
</fC03>
<fC03 i1="18" i2="X" l="FRE"><s0>Contrôle moteur</s0>
<s5>70</s5>
</fC03>
<fC03 i1="18" i2="X" l="ENG"><s0>Motor control</s0>
<s5>70</s5>
</fC03>
<fC03 i1="18" i2="X" l="SPA"><s0>Control motor</s0>
<s5>70</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>20</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>20</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>21</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>21</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>22</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>22</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Encéphale pathologie</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>23</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>23</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>24</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>24</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Système nerveux central pathologie</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>25</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>25</s5>
</fC07>
<fC07 i1="07" i2="X" l="FRE"><s0>Antiparkinsonien</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="ENG"><s0>Antiparkinson agent</s0>
<s5>26</s5>
</fC07>
<fC07 i1="07" i2="X" l="SPA"><s0>Antiparkinsoniano</s0>
<s5>26</s5>
</fC07>
<fC07 i1="08" i2="X" l="FRE"><s0>Système nerveux central</s0>
<s5>27</s5>
</fC07>
<fC07 i1="08" i2="X" l="ENG"><s0>Central nervous system</s0>
<s5>27</s5>
</fC07>
<fC07 i1="08" i2="X" l="SPA"><s0>Sistema nervioso central</s0>
<s5>27</s5>
</fC07>
<fC07 i1="09" i2="X" l="FRE"><s0>Catécholamine</s0>
<s5>28</s5>
</fC07>
<fC07 i1="09" i2="X" l="ENG"><s0>Catecholamine</s0>
<s5>28</s5>
</fC07>
<fC07 i1="09" i2="X" l="SPA"><s0>Catecolamina</s0>
<s5>28</s5>
</fC07>
<fC07 i1="10" i2="X" l="FRE"><s0>Neurotransmetteur</s0>
<s5>29</s5>
</fC07>
<fC07 i1="10" i2="X" l="ENG"><s0>Neurotransmitter</s0>
<s5>29</s5>
</fC07>
<fC07 i1="10" i2="X" l="SPA"><s0>Neurotransmisor</s0>
<s5>29</s5>
</fC07>
<fC07 i1="11" i2="X" l="FRE"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="ENG"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="11" i2="X" l="SPA"><s0>Rodentia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="FRE"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="ENG"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="12" i2="X" l="SPA"><s0>Mammalia</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="13" i2="X" l="FRE"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="13" i2="X" l="ENG"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fC07 i1="13" i2="X" l="SPA"><s0>Vertebrata</s0>
<s2>NS</s2>
</fC07>
<fN21><s1>250</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000656 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 000656 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:04-0446932
   |texte=   Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson en France (serveur d'exploration)

Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease

Role of nigral lesion in the genesis of dyskinesias in a rat model of Parkinson's disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri